Mereo BioPharma Group plc (NASDAQ:MREO) changes shares on Tuesday trading session, with a change of -7.10% or -$0.24 shares. The trading starts at $3.40 and closed at $3.38 throughout the day. The trading session low price was $3.01 and day high was $3.70 on Tuesday, June 23. After the session, the Healthcare sector daily volume shifted to 0.5 million while its average volume is 274.50K. In other hand, the MREO market cap reached to $134.17M. While, its current target price is $3.14 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 13.36% and up 159.50% for month. Its quarterly performance was 234.86% above, while its half year performance is up 147.67%. MREO yearly performance stood at positive 17.60% and fall -4.27% for year-to-date. Current recommendation for Mereo BioPharma Group plc is 1.00.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. EPS for the next year its value is -19.00.
Let’s take a look on the analyst recommendations on MREO for the current month and previous month. For the current month, 1 of 1 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $8.00-$8.00. Average target price for MREO was reached at $8.00.
Boxer Capital, LLC, Primecap Management Company and Delphi Management Partners VIII, L.L.C. are the top three holders in Mereo BioPharma Group plc (MREO) stock. On Mar 30, 2020, Boxer Capital, LLC has 2.45 million shares which valued 2.56 million. On Mar 30, 2020, Primecap Management Company owned 0.54 million shares which valued at 0.57 million. On Dec 30, 2019, Delphi Management Partners VIII, L.L.C. has a total of 0.26 million shares which valued at 0.84 million. In the end, Delphi Management Partners VIII, L.L.C. have 1.18% shares outstanding of Mereo BioPharma Group plc (MREO) on Dec 30, 2019. The insider ownership moved to 1.06% and institutional holding shifted to 15.33%.
According to the most recent quarter report on (Dec 2019), 1 analysts estimated an average EPS of -0.26. Analyst Estimated EPS for MREO published in the report was -0.26–0.26 during the same period.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for MREO rise 49.93% for period of 200 days. SMA for 50 days was 84.22% which is showing green signal, while SMA-20 was 32.77%. The moving average value for Mereo BioPharma Group plc (MREO) is 1.6909 and 1.8947 for 200 and 50 days respectively.